Literature DB >> 12738636

Cervicovaginal neutralizing antibodies to herpes simplex virus (HSV) in women seropositive for HSV Types 1 and 2.

Francois-Xavier Mbopi-Kéou1, Laurent Bélec, Julie Dalessio, Jérôme Legoff, Gérard Grésenguet, Philippe Mayaud, David W G Brown, Rhoda Ashley Morrow.   

Abstract

Antibodies to herpes simplex virus type 1 (HSV-1) and HSV-2 of the immunoglobulin G (IgG) and IgA isotypes were detected in the cervicovaginal secretions (CVS) of 77 HSV-1- and HSV-2-seropositive but clinically asymptomatic African women by type-specific enhanced chemiluminescence Western blotting (ECL-WB). Of the 77 subjects, 34 were HIV negative, shedding HSV-2 DNA in their genital secretions; 20 were HIV positive, shedding HSV-2 DNA; and 23 were HIV negative, not shedding HSV-2 DNA. HSV-specific IgG was detected in CVS of nearly 70% of the women studied. HSV-specific IgA was found in CVS of 50% of the women studied. The distribution of CVS HSV-specific antibodies to each HSV type was highly heterogeneous, with a slight predominance of detectable IgG to HSV-1 (59%) over IgG to HSV-2 (41%), whereas the frequency of detectable IgA to HSV-1 (39%) was similar to that of IgA to HSV-2 (36%). The presence of detectable HSV-specific antibodies was inversely associated with HSV-2 DNA genital asymptomatic shedding but was not affected by HIV seropositivity. In addition, 13 of 77 (17%) CVS samples showed neutralizing activity against HSV-2, as assessed by an HSV-2 in vitro infectivity reduction assay. Neutralizing activity in CVS was associated with the presence of IgG and/or IgA antibodies to HSV-1 and/or to HSV-2 by ECL-WB. Among women whose CVS showed HSV-2-neutralizing activity, the specific activity of HSV-specific neutralizing antibodies was substantially (fivefold) higher in HSV-2 DNA shedders than in nonshedders. In conclusion, HSV-specific antibodies are frequently detected in CVS of asymptomatic African women seropositive for HSV-1 and HSV-2. A subset of these women had functional neutralizing activity against HSV-2 in their CVS. The origin of these antibodies and their role in HSV-2 disease of the female genital tract remain to be determined.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12738636      PMCID: PMC154966          DOI: 10.1128/cdli.10.3.388-393.2003

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  32 in total

1.  CD8 CTL from genital herpes simplex lesions: recognition of viral tegument and immediate early proteins and lysis of infected cutaneous cells.

Authors:  D M Koelle; H B Chen; M A Gavin; A Wald; W W Kwok; L Corey
Journal:  J Immunol       Date:  2001-03-15       Impact factor: 5.422

2.  Antigen-specific T cells localize to the uterine cervix in women with genital herpes simplex virus type 2 infection.

Authors:  D M Koelle; M Schomogyi; L Corey
Journal:  J Infect Dis       Date:  2000-08-17       Impact factor: 5.226

3.  Interactions between herpes simplex virus type 2 and human immunodeficiency virus type 1 infection in African women: opportunities for intervention.

Authors:  F X Mbopi-Kéou; G Grésenguet; P Mayaud; H A Weiss; R Gopal; M Matta; J L Paul; D W Brown; R J Hayes; D C Mabey; L Bélec
Journal:  J Infect Dis       Date:  2000-09-08       Impact factor: 5.226

4.  Selection of drug-resistant variants in the female genital tract of human immunodeficiency virus type 1-infected women receiving antiretroviral therapy.

Authors:  A Si-Mohamed; M D Kazatchkine; I Heard; C Goujon; T Prazuck; G Aymard; G Cessot; Y H Kuo; M C Bernard; B Diquet; J E Malkin; L Gutmann; L Bélec
Journal:  J Infect Dis       Date:  2000-07-06       Impact factor: 5.226

Review 5.  Immunity to herpes simplex virus: a hypothesis.

Authors:  B T Rouse; M Gierynska
Journal:  Herpes       Date:  2001-03

6.  Cervical shedding of herpes simplex virus in human immunodeficiency virus-infected women: effects of hormonal contraception, pregnancy, and vitamin A deficiency.

Authors:  S B Mostad; J K Kreiss; A J Ryncarz; K Mandaliya; B Chohan; J Ndinya-Achola; J J Bwayo; L Corey
Journal:  J Infect Dis       Date:  2000-01       Impact factor: 5.226

7.  Secretory IgA antibody in cervicovaginal secretions from women with genital infection due to herpes simplex virus.

Authors:  H Merriman; S Woods; C Winter; A Fahnlander; L Corey
Journal:  J Infect Dis       Date:  1984-04       Impact factor: 5.226

8.  Cervical and serum IgA and serum IgG antibodies to Chlamydia trachomatis and herpes simplex virus in threatened abortion: a prospective study.

Authors:  M Grönroos; E Honkonen; P Terho; R Punnonen
Journal:  Br J Obstet Gynaecol       Date:  1983-02

9.  Antibody activity to type 1 and type 2 herpes simplex virus in human cervical mucus.

Authors:  B M Coughlan; G R Skinner
Journal:  Br J Obstet Gynaecol       Date:  1977-08

10.  Genital shedding of herpes simplex virus among men.

Authors:  Anna Wald; Judith Zeh; Stacy Selke; Terri Warren; Rhoda Ashley; Lawrence Corey
Journal:  J Infect Dis       Date:  2002-10-15       Impact factor: 5.226

View more
  3 in total

1.  Psychological stress exacerbates primary vaginal herpes simplex virus type 1 (HSV-1) infection by impairing both innate and adaptive immune responses.

Authors:  Kathleen A Ashcraft; Robert H Bonneau
Journal:  Brain Behav Immun       Date:  2008-06-27       Impact factor: 7.217

2.  Serum and Cervicovaginal Fluid Antibody Profiling in Herpes Simplex Virus-Seronegative Recipients of the HSV529 Vaccine.

Authors:  Kening Wang; Lesia Dropulic; Joel Bozekowski; Harlan L Pietz; Sinthujan Jegaskanda; Kennichi Dowdell; Joshua S Vogel; Doreen Garabedian; Makinna Oestreich; Hanh Nguyen; Mir A Ali; Keith Lumbard; Sally Hunsberger; Jack Reifert; Winston A Haynes; Jaymie R Sawyer; John C Shon; Patrick S Daugherty; Jeffrey I Cohen
Journal:  J Infect Dis       Date:  2021-11-16       Impact factor: 5.226

3.  Complement Opsonization Promotes Herpes Simplex Virus 2 Infection of Human Dendritic Cells.

Authors:  Elisa Crisci; Rada Ellegård; Sofia Nyström; Elin Rondahl; Lena Serrander; Tomas Bergström; Christopher Sjöwall; Kristina Eriksson; Marie Larsson
Journal:  J Virol       Date:  2016-04-29       Impact factor: 5.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.